Irwin D. Bernstein

Appointments and Affiliations

 
 
Fred Hutchinson Cancer Research Center
Clinical Research Division
Pediatric Oncology
Member, Appointed: 1981
University of Washington
School of Medicine
Pediatrics
Professor, Appointed: 1981
Professional Headshot of Irwin D. Bernstein

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N.
PO Box 19024
D2-373
Seattle, Washington 98109-1024
United States

Contact

Phone: (206) 667-1212
Fax: (206) 667-6084
ibernste@fhcrc.org

Degrees

M.D., New York University, 1967.

Research Interests

The research in Dr. Bernstein's lab has primarily focused on developmental aspects of hematopoiesis with the specific goal of developing novel therapeutic modalities. In these efforts we have identified maturation linked cell surface antigens and have utilized this information for developing methods for targeted therapy of hematologic malignancies and for isolating and characterizing normal and malignant human hematopoietic stem cells. These studies have led to the development of stem cell transplantation using isolated CD34+ cells and for Notch ligand-induced expansion of repopulating cell numbers currently being tested in a clinical trial of cord blood transplantation. Our studies of malignant hematopoiesis have examined the clonal origin of AML and have suggested that in some patients, the leukemic cells develop from a clone of mature CD33+ progenitors, or that the leukemia involves only occasional less mature CD33- precursor cells that expand in an uncontrolled manner after maturation to a CD33+ CFC. For these patients, we have hypothesized that ablation of CD33+precursors would restore normal hematopoiesis in patients with AML. On this basis, in collaboration with Wyeth-Ayerst, we have developed a conjugate for the selective ablation of CD33+ cells and demonstrated its ability to induce remissions in at least some patients with AML, supporting the notion of the predominantly or completely normal origin of the CD33- precursors. This conjugate has been approved by the FDA and our current studies are evaluating the effects of multi-drug resistance genes and the stem cell origin of AML on the efficacy of this drug.

Current studies of normal hematopoiesis are aimed at determining methods to direct primitive hematopoietic precursors to commit to a particular maturational pathway or to self-renew. The studies focus on the role of Notch signaling in the regulation of cell fate decisions during hematopoietic differentiation. These studies have demonstrated that constitutive Notch1 signaling can enhance self-renewal and immortalization of cytokine-dependent pluripotent hematopoietic stem cells. We have further demonstrated that Notch signaling induced by interaction of hematopoietic precursor cells with exogenous Notch ligand enhances the formation of primitive multipotential precursors and are presently evaluating whether the formation of hematopoietic stem cells is also enhanced. Based on these findings we developed novel methods for enhancing the repopulating capacity of human hematopoietic precursor cells. In studies with cord blood cells, culture with engineered Notch ligand led to a substantial increase in the number of CD34+ cells and in the rate and magnitude of repopulation in immunodeficient mice. In a Phase I clinical trial in patients with hematologic malignancies, we demonstrated that these cells will provide rapid early engraftment, and hypothesize they will decrease the early transplant related morbidity and mortality seen in patients undergoing umbilical cord blood transplantation and may also contribute to improvement in overall survival.

Memberships

American Cancer Society

Recent Publications

2013
2012
2011
2010
2008